BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33651882)

  • 1. Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases.
    Martin Merinero H; Subías M; Pereda A; Gómez-Rubio E; Juana Lopez L; Fernandez C; Goicoechea de Jorge E; Martin-Santamaria S; Cañada FJ; Rodríguez de Córdoba S
    Blood; 2021 Jun; 137(25):3484-3494. PubMed ID: 33651882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulation of Factor H by Factor H-Related Protein 1 Depends on Sialylation of Host Surfaces.
    Dopler A; Stibitzky S; Hevey R; Mannes M; Guariento M; Höchsmann B; Schrezenmeier H; Ricklin D; Schmidt CQ
    Front Immunol; 2021; 12():615748. PubMed ID: 33732239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele
    Pouw RB; Gómez Delgado I; López Lera A; Rodríguez de Córdoba S; Wouters D; Kuijpers TW; Sánchez-Corral P
    Front Immunol; 2018; 9():848. PubMed ID: 29740447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement Factor H related protein 1 and immune inflammatory disorders.
    Li X; Zong J; Si S
    Mol Immunol; 2022 May; 145():43-49. PubMed ID: 35279539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy.
    Márquez-Tirado B; Gutiérrez-Tenorio J; Tortajada A; Lucientes Continente L; Caravaca-Fontán F; Malik TH; Roldán Montero R; Elías S; Saiz Gonzalez A; Fernández-Juarez G; Sánchez-Corral P; Pickering MC; Praga M; Rodríguez de Córdoba S; Goicoechea de Jorge E
    J Am Soc Nephrol; 2022 Jun; 33(6):1137-1153. PubMed ID: 35545301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
    Hyvärinen S; Meri S; Jokiranta TS
    Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.
    Martínez-Barricarte R; Heurich M; López-Perrote A; Tortajada A; Pinto S; López-Trascasa M; Sánchez-Corral P; Morgan BP; Llorca O; Harris CL; Rodríguez de Córdoba S
    Mol Immunol; 2015 Aug; 66(2):263-73. PubMed ID: 25879158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.
    Goicoechea de Jorge E; Tortajada A; García SP; Gastoldi S; Merinero HM; García-Fernández J; Arjona E; Cao M; Remuzzi G; Noris M; Rodríguez de Córdoba S
    J Am Soc Nephrol; 2018 Jan; 29(1):240-249. PubMed ID: 28993505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.
    Schramm EC; Roumenina LT; Rybkine T; Chauvet S; Vieira-Martins P; Hue C; Maga T; Valoti E; Wilson V; Jokiranta S; Smith RJ; Noris M; Goodship T; Atkinson JP; Fremeaux-Bacchi V
    Blood; 2015 Apr; 125(15):2359-69. PubMed ID: 25608561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Binding of Heparin/Heparan Sulfate Oligosaccharides to Factor H and Factor H-Related Proteins: Therapeutic Potential for C3 Glomerulopathies.
    Loeven MA; Maciej-Hulme ML; Yanginlar C; Hubers MC; Kellenbach E; de Graaf M; van Kuppevelt TH; Wetzels J; Rabelink TJ; Smith RJH; van der Vlag J
    Front Immunol; 2021; 12():676662. PubMed ID: 34489931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
    Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
    Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
    J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.
    Frimat M; Tabarin F; Dimitrov JD; Poitou C; Halbwachs-Mecarelli L; Fremeaux-Bacchi V; Roumenina LT
    Blood; 2013 Jul; 122(2):282-92. PubMed ID: 23692858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation.
    Xu B; Kang Y; Du Y; Guo W; Zhu L; Zhang H
    Front Immunol; 2022; 13():755694. PubMed ID: 35126388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder.
    Uzonyi B; Szabó Z; Trojnár E; Hyvärinen S; Uray K; Nielsen HH; Erdei A; Jokiranta TS; Prohászka Z; Illes Z; Józsi M
    Front Immunol; 2021; 12():660382. PubMed ID: 33986750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and Protein Structural Evaluation of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Perkins SJ
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):120-127.e4. PubMed ID: 32553244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.
    Tortajada A; Yébenes H; Abarrategui-Garrido C; Anter J; García-Fernández JM; Martínez-Barricarte R; Alba-Domínguez M; Malik TH; Bedoya R; Cabrera Pérez R; López Trascasa M; Pickering MC; Harris CL; Sánchez-Corral P; Llorca O; Rodríguez de Córdoba S
    J Clin Invest; 2013 Jun; 123(6):2434-46. PubMed ID: 23728178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated factor H-related protein 1 and factor H pathogenic variants decrease complement regulation in IgA nephropathy.
    Tortajada A; Gutiérrez E; Goicoechea de Jorge E; Anter J; Segarra A; Espinosa M; Blasco M; Roman E; Marco H; Quintana LF; Gutiérrez J; Pinto S; Lopez-Trascasa M; Praga M; Rodriguez de Córdoba S
    Kidney Int; 2017 Oct; 92(4):953-963. PubMed ID: 28637589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein.
    McRae JL; Duthy TG; Griggs KM; Ormsby RJ; Cowan PJ; Cromer BA; McKinstry WJ; Parker MW; Murphy BF; Gordon DL
    J Immunol; 2005 May; 174(10):6250-6. PubMed ID: 15879123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.